Prime Medicine, Inc.

Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company focused on developing genetic medicines based on Prime Editing, a next-generation gene editing technology designed to provide durable and potentially curative treatment options for patients with diseases driven by defined genetic alterations. The company's website is www.primemedicine.com.

Prime Editing represents a distinct approach to genome modification that uses a Cas9 nickase fused to reverse transcriptase and guided by prime editing guide RNAs to introduce precise edits at specified genomic locations. Unlike traditional CRISPR nuclease systems that rely on double-stranded DNA breaks, Prime Editing creates single-stranded nicks and directs incorporation of desired edits through reverse transcription, enabling targeted corrections, insertions, deletions, or replacements of DNA sequences while reducing the risk of unintended genomic disruptions such as indels or chromosomal rearrangements.

The company has constructed an integrated Prime Editing platform engineered around modular design principles, allowing core delivery and editor components to remain constant while altering program-specific guide RNAs and repair templates. This architecture is intended to support rapid iteration, standardized manufacturing, and shared toxicology and chemistry, manufacturing, and controls pathways across programs.

Prime Medicine's pipeline includes wholly owned in vivo programs targeting liver genetic diseases, specifically Wilson Disease (PM577) and alpha-1 antitrypsin deficiency (PM647), as well as early-stage discovery efforts in cystic fibrosis. The company also advances PM359, an ex vivo Prime Editing program for chronic granulomatous disease that has demonstrated clinical validation of the Prime Editing approach in human cells. Additionally, Prime Medicine maintains a collaboration with Bristol-Myers Squibb focused on applying Prime Editing to ex vivo T-cell engineering for oncology and immunology indications.

The company has received significant funding support including a $55 million upfront payment and $55 million equity investment from Bristol-Myers Squibb, as well as up to $39 million in funding from the Cystic Fibrosis Foundation to support development of Prime Editors for cystic fibrosis treatment. Prime Medicine's strategy emphasizes advancing Prime Editing programs through clinical development while leveraging platform modularity to expand into additional indications with disciplined portfolio prioritization.